Learn prompt engineering with this practical cheat sheet covering frameworks, techniques, and tips to get more accurate and ...

Anthropic just built an AI model so dangerous it had to cancel the public launch. During pre-deployment testing, the company’s newest frontier model, Claude Mythos Preview, proved so adept at hunting ...

ASCO guidance for stage IV EGFR-mutant NSCLC supports initial combination regimens (osimertinib plus chemotherapy; amivantamab plus lazertinib) to improve disease control relative to monotherapy.

The prevalence of end-stage kidney failure has been exponentially increasing, leading to a gross mismatch between the number of patients who may benefit from transplantation and the limited supply of ...

For many spine and orthopedic leaders, the ASC and outpatient migration will be a defining element of 2026. From innovations and collaborations, the ASC will be a pivotal point for spine care, ...

An updated edition of the December 16, 2025, article. An aging U.S. population is becoming a first-order driver of consumption reallocation. Going by the data from the United States Census Bureau, by ...

While autologous CAR T-cell therapies have revolutionized the treatment of hematologic malignancies, their widespread application is hindered by manufacturing complexities, high costs, and limited ...

From the advent of new innovations to shifting care models, healthcare leaders reflect on what words and trends will define the spine surgery field in 2026. The 23 leaders featured in this article are ...

Abstract: In modern software development, Python third-party libraries play a critical role, especially in fields like deep learning and scientific computing. However, API parameters in these ...

Cloud security architect and advisor Steven Smiley walked attendees through a slate of notable AWS announcements in a Virtualization & Cloud Review webcast today. The presentation held by Smiley, an ...

Nes-Ziona, Israel, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (ENLV) ( Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced ...